Article

Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson’s disease

2024-03-27

Abstract excerpt

Glucocerebrosidase (GCase) is implicated in both a rare, monogenic disorder (Gaucher disease, GD) and a common, multifactorial condition (Parkinson’s disease); hence, it is an urgent therapeutic target. To identify correctors of severe protein misfolding and trafficking obstruction manifested by the pathogenic L444P-variant of GCase, we developed a suite of quantitative, high-throughput, cell-based assays. First,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ab39d127-6be2-5e30-a966-bbe9ec693b0b
DOI: 10.1101/2024.03.22.586364

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of quantitative high-throughput screening assays to identify, validate, and optimize small-molecule stabilizers of misfolded β-glucocerebrosidase with therapeutic potential for Gaucher disease and Parkinson’s diseaseDOI 10.1101/2024.03.22.586364Read

Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.Semantic proximity Read

Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based Brain Shuttle constructSemantic proximity Read

Identification and characterization of nanobodies acting as molecular chaperones for glucocerebrosidase through a novel allosteric mechanismSemantic proximity Read

Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson Disease ResearchSemantic proximity Read

A versatile fluorescence-quenched substrate for quantitative measurement of glucocerebrosidase activity within live cells.Semantic proximity Read

Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct.Semantic proximity Read

CRISPR/Cas9 Editing for Gaucher Disease Modelling.Semantic proximity Read

Gaucher disease.Semantic proximity Read

Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease.Semantic proximity Read

Patient-Specific Midbrain Organoids with CRISPR Correction Recapitulate Neuronopathic Gaucher Disease Phenotypes and Enable Evaluation of Novel TherapiesSemantic proximity Read

A guide to selecting high-performing antibodies for GCase (UniProt ID: P04062) for use in western blot, immunoprecipitation, and immunofluorescenceSemantic proximity Read

Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.Semantic proximity Read